Search

Tifuvirtide

Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

Urea

A compound formed in the liver from ammonia produced by the deamination of amino acids. … It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.

RP01

It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … RP01 is a novel anti-IgE immunotherapy for allergic individuals.

Human Interleukin 8

Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).

Lanoteplase

MM-093

Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults

Terevalefim

Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

Bardoxolone methyl

Trafermin

ALKS 27

ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).